AURA
Aura BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Primary-source disclosures support a real clinical calendar: mid-2026 NMIBC data, mid-2026 CoMpass enrollment completion, additional 2026 proof-of-concept updates, and a defined 2H 2027 pivotal readout path, while cash of $144.2 million was said to fund operations into Q1 2027 [#8-K-2026-03-30].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -1.1.
What can break
Cash runway into Q1 2027 may tighten if trial costs rise or timelines slip.
Momentum
28
Value
41
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $14.00 · Bear $3.50
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $18.80
Why
Momentum28 · Δ7d -8.8
Value41 · Δ7d +0.1
Sentiment63 · Δ7d -1.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
28
26% active weight
Current posture
7d trendSoftening
Δ7d
-8.8
Δ21d
+9.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
63
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.1
Δ21d
-3.5
Why this grade
Composite grade D. Momentum 27.6 / Value 41.1 / Sentiment 63.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$705.44M
Beta
0.46
Shares Out
103.44M
P/E (TTM) · Derived
-3.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.75
Rev YoY
-
EPS YoY
-8.9%
Gross Margin
-
Op Margin
-
Net Debt
-$126.86M
Current Ratio
7.09
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology